Kato, Shumei http://orcid.org/0000-0003-1193-1815
Kim, Ki Hwan
Lim, Hyo Jeong
Boichard, Amelie
Nikanjam, Mina
Weihe, Elizabeth
Kuo, Dennis J. http://orcid.org/0000-0003-4154-0057
Eskander, Ramez N.
Goodman, Aaron
Galanina, Natalie
Fanta, Paul T.
Schwab, Richard B.
Shatsky, Rebecca
Plaxe, Steven C.
Sharabi, Andrew
Stites, Edward http://orcid.org/0000-0002-3783-7336
Adashek, Jacob J. http://orcid.org/0000-0003-4272-312X
Okamura, Ryosuke http://orcid.org/0000-0001-7352-8621
Lee, Suzanna
Lippman, Scott M.
Sicklick, Jason K.
Kurzrock, Razelle
Article History
Received: 24 March 2020
Accepted: 25 August 2020
First Online: 2 October 2020
Competing interests
: S.K. serves as a consultant for Foundation Medicine and receives speaker’s fees from Roche. R.E. serves as a consultant for GSK, Merck, Eisai, Clovis Oncology, AstraZenica, Pfizer and Iovance. He has received speaker fees from AstraZenica and Merck. A.S. reports research funding and honoraria from Pfizer and Varian Medical Systems, consultant fees from AstraZeneca and Jounce Therapeutics, personal fees from Merck, and is the scientific founder with equity interest in Toragen Inc. outside the submitted work. J.K.S. receives research funds from Foundation Medicine Inc. and Amgen, as well as consultant fees from Grand Rounds, Deciphera and LOXO. R.K. has research funding from Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, and Konica Minolta, as well as consultant fees from LOXO, X-Biotech, Actuate Therapeutics, Genentec, Pfizer and NeoMed. She receives speaker fees from Roche, and has an equity interest in IDbyDNA and Curematch, Inc. She is a co-founder of CureMatch and Board member of CureMatch and CureMetrix. The remaining authors declare no competing interests.